Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

7 evidence topics · 6 sources

Modeled U.S. prevalence of metastatic castration-resistant prostate cancer by clinical state, 2009 and 2020
Clinical statePrevalence, 2009Prevalence, 2020 projection
Asymptomatic or minimally symptomatic mCRPC not treated with or not progressed on chemotherapy“6745”View highlighted excerpt for this quote“8320”View highlighted excerpt for this quote
Symptomatic mCRPC not treated with or not progressed on chemotherapy“32,145”View highlighted excerpt for this quote“39,650”View highlighted excerpt for this quote
mCRPC that progressed on or after first-line chemotherapy“23,220”View highlighted excerpt for this quote“28,720”View highlighted excerpt for this quote